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Transcription factors have long been recognised as powerful regulators of mammalian development yet
it is largely unknown how individual key regulators operate within wider regulatory networks. Here we
have used a combination of global gene expression and chromatin-immunoprecipitation approaches
during the early stages of haematopoietic development to deﬁne the transcriptional programme
controlled by Runx1, an essential regulator of blood cell speciﬁcation. Integrated analysis of these
complementary genome-wide datasets allowed us to construct a global regulatory network model,
which suggested that key regulators are activated sequentially during blood speciﬁcation, but will
ultimately collaborate to control many haematopoietically expressed genes. Using the CD41/integrin
alpha 2b gene as a model, cellular and in vivo studies showed that CD41 is controlled by both Scl/Tal1
and Runx1 in fully speciﬁed blood cells, and initiation of CD41 expression in E7.5 embryos is severely
compromised in the absence of Runx1. Taken together, this study represents the ﬁrst global analysis of
the transcriptional programme controlled by any key haematopoietic regulator during the process of
early blood cell speciﬁcation. Moreover, the concept of interplay between sequentially deployed core
regulators is likely to represent a design principle widely applicable to the transcriptional control of
mammalian development.
& 2012 Elsevier Inc.Open access under CC BY license. Introduction
To enhance our understanding of metazoan development, it
will be critical to both identify cellular intermediates en route
from the pluripotent stem cell to fully differentiated mature
lineages, as well as to discover the molecular mechanisms which
control individual state transitions as cells journey down a given
differentiation trajectory. The development of blood cells from
pluripotent embryonic stem cells has served as an important
model system (Keller et al., 2002) with several key intermediate
cellular stages and major regulatory genes now known
(Ottersbach et al., 2010). The Ets family transcription factor Etv2
for example is required for the differentiation of early mesoder-
mal cells into haemangioblasts (Sumanas and Lin, 2006; Lee et al.,
2008), an intermediate cell population with both haematopoietic
and endothelial potential (Choi et al., 1998). The bHLH transcrip-
tion factor Scl (also known as Tal1) is subsequently required for
the maturation of haemangioblasts into haemogenic endothelial license. cells (Lancrin et al., 2009), an intermediate cell population with
endothelial morphology yet a strong propensity for differentiation
into haematopoietic cells. This latter maturation step is controlled
by the Runt domain transcription factor Runx1, and importantly
this endothelial-to-haematopoietic transition has been shown to
require Runx1 activity both in ES cell differentiation as well as
mouse embryo in vivo studies (Chen et al., 2009; Lancrin et al.,
2009).
Despite the accumulating knowledge on key intermediate
cellular stages and major regulators, our understanding of the
molecular mechanisms that control the important differentiation
state transitions during haematopoietic speciﬁcation remains
rudimentary. Since many of the early ‘‘decision makers’’ are
transcription factors, identiﬁcation of their target genes repre-
sents a potentially very direct route into deciphering the mole-
cular and cell biological processes underlying haematopoietic cell
fate speciﬁcation. Target gene identiﬁcation has traditionally been
approached by performing gene expression proﬁling experiments
comparing wild type with mutant cells. This approach however
does not readily distinguish direct from indirect targets. Chroma-
tin immunoprecipitation (ChIP) experiments identify regions in
the genome bound by a given transcription factor, and therefore
have the capacity to establish direct regulatory relationships
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recent coupling of ChIP experiments with high-throughput
sequencing (ChIP-Seq) has made comprehensive genome-scale
identiﬁcation of transcription factor target genes a realistic
undertaking (Barski et al., 2007; Johnson et al., 2007; Robertson
et al., 2007). Indeed, ChIP-Seq analysis has now been performed
for several key haematopoietic regulators (Cheng et al., 2009;
Fujiwara et al., 2009; Wilson et al., 2009, 2010a; Yu et al., 2009;
Heinz et al., 2010; Kassouf et al., 2010; Lin et al., 2010; Soler et al.,
2010; Li et al., 2011). Importantly however, no reports so far have
analysed genome-wide binding patterns in early developmental
cell populations. Since ChIP-Seq studies of the same factor in
different cell types have shown that binding patterns are largely
cell-type speciﬁc (Hannah et al., 2011; Palii et al., 2011), it is
imperative that such analysis will be performed in early devel-
opmental cell populations in order to enhance our understanding
of the molecular control of early cell fate speciﬁcation.
Here we have deﬁned the transcriptional programme con-
trolled by Runx1 during early stages of blood development, using
embryonic stem (ES) cell differentiation as a model system.
Integrated analysis of expression and ChIP-Seq proﬁling datasets
identiﬁed candidate direct Runx1 target genes, where those
targets that correlated with Runx1 expression were enriched for
biological functions related to haematopoietic development. By
contrast, those candidate target genes that were negatively
correlated with Runx1 expression were enriched for genes
afﬁliated with non-haematopoietic tissue development. More-
over, integrated analysis of our timecourse data with a newly
generated expression dataset for E7.5 Runx1/ embryos sug-
gested a model whereby core regulatory circuits are activated
sequentially during early development, but then function
collectively within wider regulatory networks in fully speciﬁed
blood cells.Material and methods
Cell culture and in vitro differentiation of ES cells
Runx1Venus/þ ES cells were cultured and differentiated on OP9
cells as described (Hirai et al., 2005). The following mAbs were
used for cell sorting: APC–anti-Flk1 (AVAS12), biotin–anti-VE-
cadherin (VECD1; followed by streptavidin–PE–Cy7), and PE–
anti–CD41 (MWreg30; eBioscience). AVAS12 and VECD1 were
prepared and labelled in our laboratory. Cell staining was per-
formed as previously described (Hirai et al., 2005) and dead cells
excluded by propidium iodide staining. Runx1SACRE/LacZ ES cells in
which a Runx1-LacZ allele (Tanaka et al., 2012) can be reactivated
by 4-hydroxy-tamoxifen (4OHT) were generated from E2.5 mor-
ulas as described (Bryja et al., 2006; Samokhvalov et al., 2006).
Maintenance and differentiation of Runx1SACRE/LacZ ES cells was
performed in the same manner as for the Runx1Venus/þ ES cells.
Following differentiation on OP9 feeder cells, Flk1þ cells were
collected on day 4 by cell sorting, and then recultured on Collagen
type IV dishes with or without 1 mM 4OHT. After 24 h- and
48 h-culture, all cells were harvested and collected for RNA
isolation.Haematopoietic and endothelial differentiation potential assay
For haematopoietic progenitor (HPC) colony-forming assays, 1000
cells were recultured in methylcellulose media MethoCult GF M3434
(StemCell Technologies). For endothelial differentiation, 1000 cells
were recultured on OP9 in the presence of 25 ng/ml recombinant
human vascular endothelial growth factor (rhVEGF). Endothelialcolonies were determined by immunostaining using anti-CD31 anti-
body (390) (eBioscience). To monitor B-cell and myeloid differentia-
tion, 500 cells per well were seeded on OP9 monolayer and cultured
in a-MEM supplemented with 10% FCS, 50 mM 2-ME, 10 ng/ml IL-7
and 10 ng/ml Flt3L in 24 well dishes. The supernatant was collected
and analysed by FACS Aria after 14 days. CD19 and Mac1 were used
to detect B cells and myeloid cells, respectively.
Embryo experiments
E7.5 and E8.5 embryos were dissociated using 0.25% trypsin/
EDTA, and single cell suspensions were stained by the indicated
antibodies followed by FACS analysis using antibodies against cell
surface markers as well as FDG-staining for b-GAL activity. Data
were analysed using FACSDiva (BD Bioscience) and FlowJo (Tree
Star, Ashland, OR, USA). For microarray analysis FDG/VE-cadherin
double positive cells were sorted from E7.5 Runx1LacZ/þ and E7.5
Runx1LacZ/LacZ embryos, respectively. Cells were lysed in RLT buffer
(Qiagen). RNA was puriﬁed using RNeasy micro elute column
(Qiagen). Microarray analysis was performed using the SurePrint
G3 Mouse GE platform (Agilent Technologies). For whole mount
immunostaining, E7.5 Runx1LacZ/þ and E7.5 Runx1LacZ/LacZ embryos
were ﬁxed by 2% PFA/PBS on ice for 20 min. After washing with
PBS, samples were blocked with PBST/2% skimmed milk/1% normal
donkey serum overnight. Primary antibody used was anti-CD41
(MWReg30) and secondary antibody used was donkey anti-rat IgG
Alexa647 (Invitrogen).
Quantitative RT-PCR analysis
Cells were lysed in RLT buffer (Qiagen). RNA was puriﬁed using
RNeasy micro elute column (Qiagen) and used for reverse tran-
scription by SuperScriptIII (Invitrogen). Real time- PCR was
performed by PowerSyber Green kit (ABI) using ABI 9700. The
following oligonucleotide primers were used for q-PCR: Gﬁ1b, FW
CAGGATGGGGAATCACCACTC, REV GGGGTCTGTGTGTAGCTGT;
Cldn5, FW GCAAGGTGTATGAATCTGTGCT, REV GTCAAGGTAA-
CAAAGAGTGCCA; Gata1, FW CAGAACCGGCCTCTCATCC, REV
TAGTGCATTGGGTGCCTGC; bH1, FW GAAACCCCCGGATTAGAGCC,
REV GAGCAAAGGTCTCCTTGAGGT; bMajor, FW GACCCAGCGG-
TACTTTGATAGC, REV TGAGGCTGTCCAAGTGATTCA; Runx1, FW
GCAGAACTGAGAAATGCTACCG, REV GCAACTTGTGGCGGATTTGTA.
Gene expression proﬁling and data processing
Gene-expression proﬁling of VE-cadherinþ/LacZþ cells from
E7.5 Runx1WT/LacZ or Runx1LacZ/LacZ embryos was performed using
Agilent SurePrint G3 Mouse GE microarrays. For each sample
2 biological and 2 technical replicates were generated making
8 samples in total for analysis. Details regarding sample prepara-
tion, hybridisation, and image acquisition are as follows: Brieﬂy,
VE-cadherinþ/LacZþ cells from E7.5 Runx1WT/LacZ or Runx1LacZ/
LacZ embryos were enriched/sorted by FACSAria. Total RNA was
isolated using Qiagen RNeasy Micro Kit. cDNA preparation, in vitro
transcription, labelling, hybridisation, washing, and staining steps
were performed according to standard Agilent protocols. Probes
showing 1.5 fold change with P-valueo0.05 were considered
differentially expressed. Genome-wide expression proﬁles of
4 samples (Runx1VEþ , Runx1þVEþCD41 , Runx1þVEþCD41þ
and Runx1þVECD41þ) were collected using Affymetrix Mouse
Genome 430 2.0 microarrays, and a second replicate sample set
was analysed using Agilent SurePrint G3 Mouse GE microarrays.
Details regarding sample preparation, hybridisation, and image
acquisition are as follows: Brieﬂy, 1105 undifferentiated ES cells
were cultured on conﬂuent OP9 cell layers in 10 cm dishes to induce
differentiation. After 6 day of ES cell differentiation, cultured cells
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in vitro transcription, labeling, hybridisation, washing, staining and
image processing steps were performed according to standard
Affymetrix and Agilent protocols. Quality control consisted of visual
inspection of the array image for artifacts, assessment of RNA
degradation plots, and inspection of rank versus residual plots after
normalisation and probe set summarisation. A total of 7753 genes
showed dynamic expression patterns (standard deviation across
4 conditions41.0 and expression level 4100 in at least one sample).
Expression dynamics were visualised using GEDI plots (Eichler et al.,
2003). Correlation with Runx1 expression was determined using
Pearson correlation. We analysed the datasets generated by 2 plat-
forms (Affymetrix and Agilent) individually, and only considered the
genes correlated or negatively correlated with Runx1 in both datasets.
Expression levels of 6 genes were validated by Q-RT-PCR (Fig. 1C).ChIP-Seq analysis
Three million cells were puriﬁed by cell sorting for each popula-
tion. ChIP assays were performed as described (Wilson et al., 2010b)
using Runx1 antibody ab23980-100 from Abcam. Reads were
mapped to the mouse genome build mm9 using bowtie (Langmead
et al., 2009). Custom tracks, peak positions and candidate target gene
lists are available from our website (http://hscl.cimr.cam.ac.uk/
Runx1-ChIP2011/Runx1-ChIP2011.html). Peaks were called using
MACS (Zhang et al., 2008) (paramenters:—mfold¼16, —tsize¼35,
—bw¼100, —P-value¼1e9, —gsize¼2200000000) using the IgG
sample as control, which identiﬁed 227, 195 and 1143 peaks. We
further selected high conﬁdence peaks by excluding peaks in
repeat regions resulting into 67, 51 and 747 peaks in the 3 popula-
tions (Runx1þVEþCD41 , Runx1þVEþCD41þ , Runx1þVECD41þ).
Saturation curves were generated to assure that the sequencing depth
was sufﬁcient (Supplementary Fig. 1). The correlation coefﬁcients of
peak heights between the three populations illustrate that popula-
tions 2 and 3 have very similar binding patterns (Pearson’s correlation
coefﬁcient40.80) providing a rationale to split the peaks into
2 partitions (2,3,4 and 4 only respectively; Supplementary Fig. 2).
For motif analysis, the middle 200 bp was taken and peaks with more
than 60% repetitive sequence excluded. MEME (Bailey and Elkan,
1994) was used for de novomotif discovery with standard settings on
the combined peaks from all three populations as well as the
individual populations. Matches to consensus sequences were deter-
mined as described using TFBSSearch (Chapman et al., 2004). Fig. 4
tabulates all overrepresented sequence motifs on Runx1 peaks from
all 3 populations. Intragenic and promoter (within 500 bp from TSS)
binding events were associated to the corresponding gene while
intergenic binding events were mapped to the nearest 50 and 30 genes
within 50 kb. Supplementary Fig. 3 contains a detailed analysis of the
three individual groups of peaks with respect to motif search and GO
functional enrichment analysis. As populations 2 and 3 both showed
relatively small numbers of binding events with a very high overlap
between them as well as with population 4, population 2 and 3 peaks
weremerged and referred to as ‘2,3,4’ and peaks unique to population
4 referred as ‘4 only’. Genes up- or down-regulated by Runx1
overexpression in hemangioblasts were obtained from (Sakai et al.,
2009). Supplementary Table 1 provides all 787 peaks with peak
heights in 3 samples as well Tal1, Gata2 and Fli1 binding in HPC cells.Validation of CD41 as a Runx1 target
The CD41 promoter (863 bp) was ampliﬁed from mouse DNA
(primers AGTGACTCCGTCCACAAACA and TAGGACGTTTGGGAA-
GAAGG), inserted upstream of luciferase in pGL2 and assayed as
described (Landry et al., 2008). E7.5 embryos were ﬁxed for 5 minin 2% PFA on ice, and dehydrated in increasing concentrations of
methanol/PBS. Endogenous peroxidase activity was blocked by
H2O2 treatment. After rehydration, embryos were stained with
anti-CD41, followed by goat-anti-rat Ig-HRP (Jackson ImmnoRe-
search). Signals were detected using the Peroxidase Substrate Kit
DAB (Vector Laboratories).
Accession numbers
Expression array and ChIP-Seq data have been submitted to the
NCBI Gene Expression Omnibus (accession number GSE29112).Results
Many genes dynamically expressed during early blood speciﬁcation
correlate with Runx1 expression
To gain new insights into the process of early haematopoietic
development from multipotential mesodermal precursor cells, it
will be important to gain access to puriﬁed cell populations with
increasing levels of haematopoietic commitment. To this end, we
decided to take advantage of ES cell differentiation systems based
on an ES cell line model that contains a Venus ﬂuorescent reporter
gene knocked into one of the endogenous Runx1 alleles (see
Fig. 1A). Of note, even though the timing of haematopoietic stem
cell (HSC) development is slightly altered in Runx1þ / embryos
(Cai et al., 2000), the stem and progenitor cells generated are
functional. Like other transcription factor knock-ins with pheno-
types in heterozygous mice such as Scl and Brachyury (Stott et al.,
1993; Curtis et al., 2004; Lacombe et al., 2010), the Runx1Venus/þ
ES cells therefore represent an effective means to purify cell
populations of interest, which are otherwise not accessible.
Following in vitro differentiation, cells can be puriﬁed by ﬂow
cytometry based on their levels of Venus ﬂuorescence as a
surrogate marker for Runx1 expression, and through the use of
antibodies against cell surface markers can be further fractionated
into cell populations with deﬁned biological properties.
As shown in Fig. 1(B), Runx1Venus/þ ES cells expressed haema-
topoietic (CD41) and endothelial (VE-cadherin) lineage markers
following 6 days of OP9 co-culture. Thus we decided to use this
approach to purify four cell populations: Population 1 contained
Runx1-Venus negative/VE-cadherin positive cells, a population
recognised as being committed to the endothelial lineage. Popu-
lation 2 contained Runx1-Venus positive/VE-cadherin positive/
CD41 negative cells, corresponding to lateral mesodermal pro-
genitors with both endothelial and haematopoietic differentiation
potential. Population 3 contains Runx1-Venus positive/VE-cad-
herin positive/CD41 positive cells, and thus represents a popula-
tion more committed to the haematopoietic lineage, but still
retaining some endothelial characteristics. Population 4 contains
Runx1-Venus positive/VE-cadherin negative/ CD41 positive cells
which represent haematopoietic progenitor cells. To further
corroborate these phenotypic characteristics, cells from each
population were isolated by ﬂow cytometry and analysed by
performing colony forming assays and studying the expression of
marker genes. Comprehensive Q-RT-PCR analysis demonstrated
speciﬁc expression of erythroid genes only in population 4, and
downregulation of the endothelial marker claudin 5 in popula-
tions 2–4 (Fig. 1C).
To further investigate the haematopoietic and endothelial
potentials of these 4 populations, sorted cells were cultured in
methylcellulose medium to investigate haematopoietic progeni-
tor cell (HPC) colony-forming potential. As shown in Fig. 2(A),
populations 1 and 2 (Runx1/VE-cadherinþ and Runx1þVE-
cadherinþCD41) had no haematopoietic potential using this
Fig. 1. Isolation of cell populations and validation by gene expression analysis. (A) ES cell differentiation using an ES cell line model containing a Venus reporter gene
knocked into one of the endogenous Runx1 alleles. The ES cells were plated onto OP9 cells without LIF and differentiated for 6 day. (B) FACS plots from day 6 Runx1venus/þ
ES cells differentiated on OP9. Puriﬁcation of four cell populations of increasing haematopoietic potential using ﬂow cytometry (1) Runx1VEþFlk1þ , (2)
Runx1þVEþCD41 , (3) Runx1þVEþCD41þ and (4) Runx1þVECD41þ . (C) Populations 1–4 were validated using quantitative RT-PCR analysing the expression of
Runx1, Gata1, bMajor, bH1, Gﬁ1b and Cldn5.
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Fig. 2. Endothelial and haematopoietic potentials of the day 6 differentiated Runx1Venus/þ ES cell populations and gene expression dynamics during early blood
speciﬁcation. (A) The 4 sorted populations were cultured in methylcellulose. At day 10 of culture, haematopoietic colonies were counted. (B) Lymphoid potential of the
3 Runx1 expressing populations. The 3 Runx1 expressing populations were sorted and cultured on OP9 in the presence of 10 ng/ml IL-7 and Flt3L for 14 day. Non-adherent
cells were collected from the culture and analysed by ﬂow cytometry for the expression of B220 and CD19. (C) Endothelial cell colony forming potential of the
4 populations. The 4 populations were sorted and cultured on OP9. Endothelial colonies judged by immunostaining against Pecam1 were counted after 4 day. (D) Global
analysis of changes in gene expression proﬁles of the four sorted samples represented using gene expression dynamics investigator (GEDI (Eichler et al., 2003)) plots with a
colour gradient (blue representing lowly expressed genes to red representing highly expressed genes). The white arrowhead indicates the position of Runx1, the expression
of which increases across the four samples as expected. (E) Correlation analysis of dynamically expressed genes in relation to Runx1 expression; (i) Pearson’s correlation
coefﬁcients (PCC) for all dynamically expressed genes with respect to Runx1 showing that most of these genes correlate positively or negatively with Runx1 expression.
(ii) Control analysis with randomised samples conﬁrming that the coherent dynamic transcriptome with respect to Runx1 is valid.
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cadherinþ/CD41þ and Runx1þ/VE-cadherin/CD41þ) had col-
ony-forming potential, but CFU-mix colonies were detected only
in population 3 (Runx1þVE-cadherinþCD41þ). Next we exam-
ined lymphoid differentiation potential of the three 3 Runx1þ
populations by reculturing cells on an OP9 stromal layer in the
presence of IL-7 and Flt3L for 14 days. CD19þB220þ cells were
detected in the two Runx1þVE-cadherinþ populations (popula-
tions 2 and 3) (Fig. 2B), suggesting that only those two popula-
tions have deﬁnitive haematopoietic potential. Population 2 had
no haematopoietic potential in methylcellulose medium, but
could generate B lymphoid cells in OP9 culture, thus suggesting
that these cells require OP9-support to differentiate into the
haematopoietic lineage, a notion consistent with previous obser-
vations (Hashimoto et al., 2007). We also examined the endothe-
lial potential of all 4 populations using reculture of sorted cells on
OP9 in the presence of VEGF. After 4 days of culture, immunos-
taining using anti-Pecam antibody revealed Pecamþ colonies only
using cells from the three VE-cadherinþ populations (populations
1– 3; see Fig. 2(C)). Taken together, these data support a model
whereby population 1 (Runx1/VE-cadherinþ) is likely restricted
to endothelial potential, populations 2 and 3 have both deﬁnitive
haematopoietic (lymphoid) and endothelial potential and popula-
tion 4 appears restricted to primitive haematopoietic (erythroid/
myeloid) potential.
To obtain insights into the global transcriptional programmes
characteristic for these four early developmental cell populations,
we next performed gene expression proﬁling on all four popula-
tions. When interrogated across the four different populations,
over 6000 genes displayed dynamic expression patterns. Analysis
using the Gene Expression Dynamics Inspector (GEDI) tool
(Eichler et al., 2003) demonstrated that dynamically expressed
genes largely fall into two categories, those that are progressively
downregulated and those that are upregulated when the four
populations are arranged from population 1 to 4 (see Fig. 2D). As
expected, Runx1 itself was amongst the upregulated genes (see
white arrowhead in left-hand panel of Fig. 2D) thus providing
internal consistency between endogenous Runx1 expression and
the cell sorting strategy based on the knock-in transgene.
To deﬁne all genes whose dynamic expression proﬁle across
the four populations might be under the control of Runx1, we
next calculated Pearson correlation coefﬁcients for all dynami-
cally expressed genes in relation to Runx1. As shown in Fig. 2(E),
the majority of these genes showed either positive correlation or
negative correlation with Runx1 expression, and was thus con-
sistent with Runx1-mediated activation and repression, respec-
tively. However, inference based on correlated gene expression
alone is unable to distinguish direct regulation from indirect
regulation or indeed simple correlation without any regulatory
linkage. It is unlikely that Runx1 on its own is responsible for
virtually all of the gene expression dynamics seen across the four
populations analysed here, thus suggesting that additional
approaches would be required to identify the subset of genes
directly controlled by Runx1.
Genome-wide analysis demonstrates dynamic recruitment of Runx1
protein to its target sites during haematopoietic speciﬁcation
Computational analysis had suggested that transcriptional
datasets alone would not be sufﬁcient to identify the transcrip-
tional programme downstream of Runx1 during early haemato-
poietic speciﬁcation. The direct demonstration of Runx1 protein
binding to regulatory regions within candidate target gene loci
would provide highly complementary information, which can be
obtained at genome-scale by ChIP-Seq. We therefore puriﬁed
3 million cells from each of the Runx1 expressing populations2–4 (Fig. 1D), prepared chromatin and performed ChIP experi-
ments using an antibody against endogenous Runx1 protein. A
parallel ChIP assay was also performed on 10 million unsorted
cells using a non-speciﬁc IgG antibody to serve as a negative
control for subsequent analysis of Runx1 binding.
Analysis of ChIP material by quantitative real-time PCR demon-
strated signiﬁcant binding of Runx1 protein to the Runx1 þ23
enhancer (Nottingham et al., 2007) in cell population 4, with less
binding in population 3 (See Fig. 3A). We therefore proceeded to
analyse all three Runx1 ChIPs as well as the IgG negative control
sample by high-throughput sequencing using the Illumina Genome
Analyzer II platform. DNA sequencing of ChIP material provided
13.4 million, 9.8 million, 16.6 million and 9.3 million uniquely
mappable reads for populations 2, 3, 4 and the IgG control sample,
respectively, thus demonstrating that sufﬁcient sequencing depth
had been achieved to analyse genome-wide binding patterns
of Runx1.
To permit genome-wide analysis of regions bound by Runx1
protein, binding peaks were identiﬁed using software tools
designed to take advantage of the negative control sample for
elimination of false positive peaks of enrichment (see Material
and methods). A total of 787 regions were identiﬁed to be bound
by Runx1 in at least one of the three samples, with most peaks
predicted to only be present in population 4 (see Supplementary
Table 1). To further explore these results, Runx1 binding across all
787 peak regions was visualised using heat-maps displaying the
strength of binding across 10 kb segments centred on each peak
region (see Fig. 3B). Heat map analysis indeed supported a model
whereby Runx1 binding in the earlier populations is absent or
highly transient except for a small subset of peaks, with the large
majority of regions only showing robust binding in population 4.
In order to further validate the 787 Runx1-bound regions
deﬁned above, we compared them to Runx1 binding events
previously mapped in the haematopoietic progenitor cell line
HPC7 (Wilson et al., 2010a). 37% of the new peaks coincided with
regions also bound by Runx1 in the HPC7 cell line (Supplementary
Fig. 4), thus providing additional support for the validity of the
new data. Moreover, of 839 Runx1 candidate target genes identi-
ﬁed by Hollenhorst et al. (2009) in the human leukaemia cell line
Jurkat , 503 overlapped with the candidate Runx1 target
genes deﬁned here, thus demonstrating a very signiﬁcant overlap
(P-value 1.2e10) (Supplementary Fig. 6). In order to compare
Runx1 levels in the ES-cell derived populations 1–4 with the
HPC7 cell line, we performed a ChIP assay on the HPC7 cells
using the same conditions as used for the ES-derived populations,
and then performed quantitative comparisons by Q-PCR. Even
the ES-cell derived population with the highest Runx1 binding
(e.g., population 4) consistently displayed only about half as
much Runx1 binding as the HPC7 cell line (see Supplementary
Fig. 10), consistent with the notion that the relatively small
numbers of Runx1 peaks in the ES-cell derived populations are
at least in part related to smaller amounts of Runx1 protein
available for binding.
We next analysed Runx1 binding peak locations relative to
gene coordinates, which demonstrated that the majority of peaks
were not associated with promoters but instead found either
within or between genes. This pattern of distribution was parti-
cularly evident for those peaks already bound in populations
2 and/or 3 where only 3 out of 100 peak regions were found to
overlap promoter sequences (see Fig. 3C). By contrast, the
proportion of promoter to non-promoter peaks was nearly even
for those Runx1 peak regions bound speciﬁcally in population 4.
To explore the nature of Runx1-bound regions further, we
performed de novo motif discovery to identify overrepresented
sequence motifs when compared with control sequences. The
most signiﬁcantly overrepresented motif (see Fig. 4A)
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(A) Validation of Runx1 ChIP assays. Runx1 ChIP assays in populations 2–4 were validated using quantitative PCR with primer pairs for a region known to be bound by
Runx1 (þ23 kb, blue bars) and a negative control region (þ30 kb, green bars) (Wilson et al., 2009). (B) Heatmaps displaying density proﬁles of Runx1 binding in
populations 2–4 to all 787 peak regions, with the peak summit at the center shown with 5 kb ﬂanking sequence either side. Few peaks occur in populations 2 and 3 with
most peaks showing strong binding in population 4. (C) Analysis of peak locations with respect to genes. Peaks shared by all populations are rarely found in promoters
whereas peaks found in population 4 are equally distributed between promoters and intragenic regions. The pie charts on the right show proportion of peaks in promoters
(red), intragenic (green) and intergenic (blue).
Y. Tanaka et al. / Developmental Biology 366 (2012) 404–419410corresponded to a perfect match to the Runx1 consensus binding
sequence TGYGGT, thus providing independent conﬁrmation of
the ChIP-Seq data quality. One of the two further overrepresented
motifs was a perfect match to the WGATAA consensus sequence
for the GATA family of transcription factors consistent with a
recent report suggesting that Gata2 may recruit Runx1 to target
regions lacking Runx1 consensus motifs (Wilson et al., 2010a).
This notion is supported further by the signiﬁcant overlap (P-
value 2.0e31) between the Runx1 targets deﬁned here and
Gata2 target sites identiﬁed previously in the HPC cells(Supplementary Fig. 5). Moreover, of 1138 WGATA motifs present
in the Runx1-bound regions, 403 were situated in an extended
WGATAA consensus (expected—1138/4E285), thus suggesting
that A is commonly found immediately 30 of the GATA core in our
data similarly to what has been seen before in erythroid cells
(Fujiwara et al., 2009). The ﬁnal overrepresented motif contained
a longer consensus sequence, which contained within its 30
portion the sequence TGTAGT and therefore deviates from the
TGTGGT Runx1 consensus by only a single mismatch. This motif
occurs in 10% (79) of all Runx1-bound regions and a very similar
Fig. 4. Motif discovery reveals a novel motif enriched in promoters. (A) De novo
motif discovery reveals three overrepresented motifs with their reverse compli-
ment in Runx1-bound regions, two of which correspond to the Runx and GATA
consensus motifs. (B) Hierarchical clustering of all regions bound by Runx1 based
on binding proﬁle partitions (populations 2–4 versus population 4 only, location in
promoters (second column), and presence of the new, Runx1 or Gata motif from
(C) as determined using TFBSSearch (Chapman et al., 2004). (C) Venn diagram of
peak overlaps of peaks for the three populations speciﬁcally highlighting high
overlap between populations 2 and 3 (see also Supplementary Fig. 2).
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binding in human blood stem/progenitor cells (Yu et al., 2011).
To investigate potential dependencies between the various
Runx1 binding peak characteristics identiﬁed above, we generated
a binary table cataloguing peak annotation, and then performed
hierarchical clustering. This analysis emphasised our observation
that Runx1 binding to promoters is rare for regions bound in
populations 2–4, yet relatively common for regions bound in
population 4 only (see Fig. 4B). Moreover, even though the Runx1
consensus motif is highly overrepresented and therefore readily
recovered by de novo sequence motif discovery, it was only present
in just over half of all the regions bound by Runx1 suggesting
binding via novel motifs or recruitment by other factors. Of note,
the novel TGTAGT containing motif (see above) was almost entirely
restricted to regions that did not contain the conventional Runx1
consensus motif thus consistent with the notion that it may
represent a potentially new motif for Runx1. Moreover, this new
motif was found much more often in promoter than non-promoter
peaks (P-value: 4.8e72) suggesting that Runx1 binding to the
TGTAGT site may be facilitated through simultaneous binding of apromoter-speciﬁc factor to the adjacent TGGGA sequence, that was
also highly conserved within this novel motif (see Fig. 4A,B).
Fig. 4C highlights a high overlap between Runx1-bound
regions in populations 2 and 3 providing a rationale for classifying
peaks into two partitions (‘2,3,4’ and ‘4 only’) (see Supplementary
Fig. 2). This partition was further supported through Pearson
correlation analysis of peak height, since ‘2,3,4’ peaks have
comparable peak heights in all three populations where as ‘4
only’ peaks are substantially higher in population 4 than in
populations 2 and 3. This observation suggests that increased
expression of Runx1 in population 4 does not increase the binding
strength at previously occupied locations (‘2,3,4’ peaks) but
results in Runx1 binding to new genomic locations (‘4 only’
peaks) (see Supplementary Fig. 11). Importantly, de-novo motif
discovery algorithms revealed overrepresentation of the Runx1
consensus motif in the Runx1-bound regions for each population
thus validating both the ‘2,3,4’ and ‘4 only’ peak sets (see
Supplementary Fig. 3).Integration of expression and ChIP-Seq datasets deﬁnes a candidate
Runx1 target gene set
To delineate the candidate target gene set likely to be directly
responsible for mediating Runx1 function during early haemato-
poietic development, we next performed an integrated analysis of
the expression and ChIP-Seq datasets. We mapped the Runx1
binding peaks from all three populations (population 2, popula-
tion 3 and population 4) to genes which yielded a total combined
set of 839 candidate targets (see Supplementary Table 2). We
then calculated Pearson correlation coefﬁcients for all 839 candi-
date targets relative to Runx1 expression across populations 1 to
4. This analysis demonstrated strong enrichment for genes corre-
lating with Runx1 expression, and also a minor enrichment for
genes with negatively correlated expression (see Fig. 5A). More-
over, when analysed as a fraction of all expressed genes, those
genes that correlated with Runx1 expression were twice as likely
to have a Runx1 ChIP-Seq binding peak, than those not correlating
with Runx1 expression (see Fig. 5B). However, only approxi-
mately 6% of all correlated genes had a binding peak suggesting
that only a relatively small subset are direct Runx1 targets. The
Runx1 ChIP-Seq data therefore appear to provide a powerful ﬁlter
for Runx1 target gene identiﬁcation by reducing candidate targets
from over 2900 based on correlated expression alone to just 219
based on the combination of correlated expression and Runx1
binding. Similarly, analysis of the expression data alone had
yielded over 1100 negatively correlated genes, yet only 65 of
these were classiﬁed as direct targets based on the combination of
Runx1 ChIP-Seq peaks and negatively correlated expression.
To further explore the potential functionality of Runx1 candi-
date target genes deﬁned above, we next performed Gene
Ontology analysis to identify biological functions overrepresented
in the 219 Runx1-bound correlated and also in the 65 Runx1-
bound negatively correlated genes (gene lists are provided in
Supplementary Table 2). As shown in Fig. 5C, both myeloid and
erythroid differentiation were overrepresented in the Runx1-
bound positively correlated gene set, as well as a number of
additional biological functions including chromatin modiﬁcation
and RNA processing (see Supplementary Fig. 7 for full Gene
Ontology tree). By contrast, non-haematopoietic developmental
processes (muscle, neural and liver) were overrepresented in
the Runx1-bound negatively correlated gene-set, together with
biological functions related to cell morphogenesis (see
Supplementary Fig. 7 for full Gene Ontology tree). Taken together
therefore, Gene Ontology analysis is consistent with the notion
that Runx1 upregulated genes drive haematopoietic development,
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Fig. 5. Integration of expression and ChIP-Seq datasets deﬁnes a candidate Runx1 target gene set. (A) Histogram showing correlation with Runx1 dynamics for all genes
(red) and Runx1 bound genes (blue) (scaled appropriately for superposition) with correlation (0.8) and negative correlation (0.6) cut-offs. (B) Fraction of Runx1 bound
genes in not-correlated, negatively correlated and correlated gene- sets respectively (as deﬁned using the cut-offs in (A). The gradual increase supports the regulatory role
of Runx1 inferred from binding events. (C) Analysis of putative gene functions using gene ontology overrepresentation (Al-Shahrour et al., 2008) reveals biological
functions consistent with haematopoietic development for correlated Runx1-bound genes, and non-haematopoietic fates for negatively correlated Runx1 bound genes. See
Supplementary Fig. 3 for Gene Ontology analysis results using peak regions from single populations.
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haematopoietic tissue development.
Intersection of the Runx1 candidate target gene set with Runx1 /
expression proﬁling suggests step-wise establishment of the
haematopoietic transcriptional programme
Having identiﬁed a core set of Runx1 candidate target genes
during the early stages of haematopoietic development based on
correlated expression and ChIP-Seq peaks, we next investigated
the relationship of this target gene set with Runx1 loss of function
expression proﬁling data. To this end, we puriﬁed RNA from ﬂow
sorted VE-cadherinþ/Runx1þ cells obtained from E7.5 Runx1
heterozygous and Runx1 null embryos, and performed microarray
gene expression proﬁling to identify all genes affected by loss of
Runx1 (Fig. 6A). Using a fold expression change threshold of 1.5,
311 genes showed reduced expression in the Runx1/ cells,
whereas 602 genes were upregulated (see Supplementary
Table 3). Since both analyses of Runx1-correlated expression aswell as expression changes in Runx1/ cells will capture both
directly and indirectly controlled genes, we next intersected both
expression datasets with the Runx1 ChIP-Seq data. A total of
80 genes positively correlating with Runx1 expression in ES cell
differentiation assays showed reduced expression in E7.5
Runx1/ cells, and 20 of these were also identiﬁed as Runx1
targets in our ChIP-Seq screen (Fig. 6B). Similarly, of 1160 genes
negatively correlating with Runx1 expression, 137 were upregu-
lated in Runx1/ cells from E7.5 embryos, and 9 of these were
bound by Runx1 in the ChIP-Seq (Fig. 6C).
In order to provide further evidence that the Runx1 targets
reported here represent a high conﬁdence set of target genes, we
investigated how many of the genes shown in Fig. 6(B) are
dependent on sustained Runx1 expression in fully developed
blood stem/progenitor cells. To this end, we compared the Runx1
targets identiﬁed here with a gene list recently reported by Cai
et al. (2011), who reported gene expression proﬁles from wild
type and Runx1/ blood stem/progenitor cells isolated from
bone marrow of conditional Runx1 knock-out mice . Of note, 7
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Fig. 6. Intersection of Runx1-correlated and Runx1-bound genes with Runx1/ expression proﬁling suggests a step-wise establishment of the haematopoietic
transcriptional programme. (A) Identiﬁcation of differentially expressed genes in E7.5 Runx1þ / and Runx1 / embryos. VE-cadherinþ/Runx1þ cells were ﬂow sorted
from E7.5 mouse embryos and differentially expressed genes were identiﬁed by microarray expression proﬁling. The pink square indicates the gate used for cell sorting.
(B) Intersection of gene expression and ChIP-Seq datasets identiﬁes a candidate gene set positively controlled by Runx1. ‘Pos.Corr.’, genes positively correlating with Runx1
expression from Fig. 5(A) (e.g., using expression proﬁling data from in vitro differentiated ES cells); ‘KO down’, genes at least 1.5-fold lower in E7.5 Runx1/ than
Runx1þ / from (A) (e.g., using primary cells derived from mouse embryos); ‘Bound’, genes bound by Runx1 in one or more of the three populations from Fig. 3C)
Intersection of gene expression and ChIP-Seq datasets identiﬁes a candidate gene set negatively controlled by Runx1. ‘Neg.Corr.’, genes negatively correlating with Runx1
expression from Fig. 5(A) (e.g., using expression proﬁling data from in vitro differentiated ES cells); ‘KO up’, genes at least 1.5-fold higher in E7.5 Runx1/ than Runx1þ /
from A (e.g., using primary cells derived from mouse embryos); ‘Bound’, genes bound by Runx1 in one or more of the 3 populations from Fig. 3D) The majority of Runx1
positively controlled genes from Fig. 6B are bound by the Scl/Gata2/Fli1 triad in haematopoietic progenitor cells. The diagram shows all Runx1-positively controlled genes
in red and negatively controlled genes in blue. Links are also drawn for those genes bound by the Scl/Gata2/Fli1 triad in haematopoietic progenitor cells, showing binding
for 18/20 Runx1 positively controlled and 3/10 Runx1-negatively controlled genes. Only one of the genes (Mettll3) has a Runx1 peak bound in populations 2–4.
Y. Tanaka et al. / Developmental Biology 366 (2012) 404–419 413out of 19 of our bound and positively-correlated (Itga2b, Hexim 2,
Tmem56, Runx1, Mettl8, Gﬁ1b, Gata1) and 3 out of 10 of our
bound and negatively-correlated (Camsap1l1, Casp4, Sbf2)
showed differential expression, thus demonstrating dependence
on sustained Runx1 expression for a high proportion of the Runx1
candidate target genes identiﬁed in our study.The earliest mesodermal fate restriction en route to blood
involves the formation of the haemangioblast, which at the
molecular level is characterised by a core regulatory circuit
composed of the Scl, Gata2 and Fli1 transcription factors forming
a densely connected triad replete with positive feedback loops
(Pimanda et al., 2007; Narula et al., 2010). Runx1 itself is not
Y. Tanaka et al. / Developmental Biology 366 (2012) 404–419414expressed at this early stage (Lancrin et al., 2009). To explore
further the potential implications of sequential activation of key
regulators, we next interrogated recently published ChIP-Seq data
from an ES-cell derived haematopoietic progenitor cell line
(Wilson et al., 2010a). Of note, 18 of the 20 genes positively
controlled by Runx1 were also bound by the Scl/Gata2/Fli1 triad
in the haematopoietic progenitor cell line, while the same
Scl/Gata2/Fli1 binding was seen for only 3 of the 10 genes
negatively controlled by Runx1 (Fig. 6D). A total of 139/687 ‘4-
only’ peaks were bound Scl, Gata2 and Fli1, with a further 413
bound by at least 1 factor in the HPC cell line, thus constituting a
set of genomic regions well-recognised as transcription factor
targets in blood progenitor cells. By contrast, only 6 of the 100
‘2,3,4’ peaks were bound by Scl, Gata2 and Fli1 in the HPC cell
line, with a further 27 bound by at least one factor. This analysis
suggests that Scl, Gata2 and Fli1 mediate Runx1 recruitment only
to a subset of the ‘2,3,4’ peaks, while they may act in this way for
a large proportion of the ‘4-only’ peaks. Such a model would be
consistent with our observation that Gata and Ets motifs were
overrepresented in the peaks from population 4, but not popula-
tions 2 and 3 (see Supplementary Fig. 3). Moreover, we recently
reported that the earliest stages of Runx1 expression are inde-
pendent of Scl, Gata2 and Fli1, thus suggesting Runx1 functions
both alone and in conjunction with the Scl/Gata2/Fli1 triad
(Kataoka et al., 2011). Taken together therefore, our data suggest
a model whereby some early Runx1 targets are expressed
independently of the Scl/Gata2/Fli1 triad, but the majority of
haematopoietic genes induced by Runx1 will ultimately be con-
trolled by both Runx1 and the Scl/Gata2/Fli1 triad.
Expression of CD41 correlates with sequential activation of core
regulatory circuits
The integrin alpha 2b gene also known as glycoprotein IIb or
CD41 was one of the genes identiﬁed in the previous section as
bound by both the SclGata2/Fli1 triad and Runx1 in haemato-
poietic progenitor cells, yet correlating in expression speciﬁcally
with Runx1 and therefore not expressed as early as Scl. Closer
inspection of the Runx1 ChIP-Seq data across the CD41 gene locus
demonstrated speciﬁc recruitment of Runx1 to the CD41 promo-
ter region with robust Runx1 binding seen in population 4 (see
Fig. 7A). CD41 is not expressed in the earlier haemangioblast
populations that express the Scl/Gata2/Fli1 triad, yet the CD41
promoter is bound by those three factors as well as Runx1 at the
later haematopoietic progenitor stage (see Fig. 7D).
To further investigate the responsiveness of the CD41 promo-
ter to Scl and Runx1, we generated a CD41–promoter construct
fused to the luciferase reporter gene and performed transactiva-
tion experiments. As shown in Fig. 7(B), transactivation with Scl
did not enhance activity of the CD41 promoter. By contrast,
Runx1 was able to enhance CD41 promoter activity 2-fold, and
this enhancement was even greater (approximately 3-fold), when
both Runx1 and Scl were expressed. Differential responsiveness of
the CD41 promoter to Runx1 and Scl was therefore consistent
with a critical role for Runx1 in initiating CD41 expression,
whereas both Runx1 and Scl might collaborate in the mainte-
nance of CD41 expression. Furthermore, Runx1-mediated trans-
activation of the CD41 promoter was corroborated further since it
followed a dose-response pattern (Supplementary Fig. 8).
To obtain in vivo evidence for the proposed critical role of
Runx1 in initiating CD41 expression, we next investigated CD41
expression in Runx1 mutant embryos. When we analysed E7.5
wild-type mouse embryos by whole mount immunostaining
using antibodies against CD41, CD41 expression was observed
within the haematopoietic domain of extraembryonic tissue
destined to form the yolk sac blood islands. By contrast, CD41immunostaining was signiﬁcantly reduced in Runx1 mutant
embryos (see representative embryos shown Fig. 7C). To corro-
borate these ﬁndings, we next performed ﬂow cytometric analysis
of both wild type and mutant E7.5 mouse embryos using
antibodies against CD41 as well as the endothelial marker
CD31. It had previously been reported that E7.0 mouse embryos
contain a CD41-dim population, whereas E8.25 embryos contain
both CD41-dim and CD41-bright populations (Ferkowicz et al.,
2003). We therefore performed extensive FACS analysis of 7 dis-
tinct and consecutive developmental stages between E7.0 and
E8.5 (see Fig. 8A), in order to interpret analysis of Runx1 embryos
within the context of the dynamic changes in CD41 expression.
Analysis of E7.5 embryos (where most CD41 expressing cells are
CD41-dim) showed that CD31 expression was unaffected in
Runx1 mutant embryos, whereas CD41 expressing cells were
severely reduced (Fig. 8B). Analysis of E8.5 embryos (where some
CD41 expressing cells are CD41-high) showed that CD31 expres-
sion was again unaffected in Runx1 mutant embryos. CD41
expressing cells were again severely reduced, particularly so for
CD41-high cells (see Fig. 8B). Flow cytometry analysis therefore
corroborated the immuno-histological studies. Moreover, since
Runx1 mutant embryos express haemangioblast marker genes
including Scl, our experiments provide in vivo evidence that the
transcriptional programme initiated by Scl is not sufﬁcient to
mediate CD41 expression in E7.5 mouse embryos, which instead
critically depends on Runx1 activity.
Upregulation of CD41 expression by Runx1 induction in ES cell
differentiation culture
CD41 expression was severely reduced in E7.5 Runx1-null
embryos. Chip-Seq analysis and CD41 promoter assays showed that
Runx1 bound to the CD41 promoter region and upregulated CD41
expression (see Supplementary Fig. 9 for a schematic representa-
tion). Next we examined whether Runx1-reactivation in Runx1-null
ES cells was able to upregulate CD41 expression as further
conﬁrmation for this regulatory link within an in vitro ES cell
differentiation culture system. To this end, we established Runx1-
reactivable ES cells (Runx1SACRE/LacZ ES cells) from a transgenic
mouse model where a Runx1-LacZ null allele can be reactivated
by 4-hydroxy-tamoxifen (4OHT) (Samokhvalov et al., 2006; Tanaka
et al., 2012). When using wild-type ES-cells, a subset of Flk1þ cells
start to express Runx1 at around day 4 of ES cell differentiation
culture on OP9 (Hirai et al., 2005). Therefore, we sorted Flk1þ cells
after 4 days of culture on OP9, and then recultured cells on collagen
type IV dishes with or without 4OHT. After 24 h and 48 h culture,
we collected cells for gene expression analysis, which showed
speciﬁc induction of Runx1 in the 4OHT treated cells. Subsequent
analysis of CD41 mRNA levels showed minor but reproducible
upregulation, but nevertheless demonstrated CD41 expression to
correlate with Runx1 (Fig. 8C). Moreover, similar results have been
reported for Pu.1 using a tetracycline-inducible Runx1-reactivation
ES-cell based model (Hoogenkamp et al., 2009), thus further validat-
ing our strategy of intersecting ChIP-Seq data with both ES-cell and
embryo-derived expression datasets.Discussion
Transcription factors are widely recognised as key drivers of
early development, where they function as central components of
gene regulatory networks that execute the genomic regulatory
blueprint for cellular differentiation (Davidson and Levine, 2008).
Genetic perturbation experiments of key regulatory transcription
factors often result in the failure to develop entire cell lineages.
One such critical transition step has been revealed through
Fig. 7. Validation of CD41 as a direct target of Runx1 during early haematopoietic development. (A) Runx1 is recruited to the CD41 promoter during haematopoietic
development. Raw ChIP-Seq read data were transformed into density plots and displayed as custom tracks within the UCSC genome browser above the UCSC track for gene
structure (IgG control at the top followed by Runx1 data for populations 2–4). (B) The CD41 promoter can be activated by Runx1 and Runx1 together with Scl. The murine
CD41 promoter region was inserted upstream of a luciferase reporter gene, and its activity monitored following co-transfection with Scl and Runx1 expression constructs
in 293T cells. Relative luciferase activity values are normalised to empty vector control transfections. Values shown represent the average of 3 independent experiments,
each performed in triplicate. (C) Early CD41 expression in mouse embryos critically depends on Runx1 activity. Immunostaining for CD41 in Runx1 heterozygous and
Runx1 homozygous knock-in E7.5 embryos shows loss of CD41 expression in the absence of Runx1. (D) Scl, Gata2, Fli1 and Runx1 bind to the CD41 promoter in the murine
haematopoietic progenitor cell line HPC7. ChIP-Seq results are displayed as density proﬁle custom tracks within the UCSC genome browser as for A.
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showing it to be indispensable for the development of blood stem/
progenitor cells from haemogenic endothelial cells (Swiers et al.,
2010). To understand the molecular mechanisms underlying this key
developmental transition, identiﬁcation of physiological Runx1 target
genes in early cell populations will be essential. The genome-wide
Runx1-centric expression and DNA binding data reported here
represent the ﬁrst integrated genome-scale analysis of complemen-
tary expression and ChIP-Seq proﬁles for any major haematopoietic
regulator during a time-course of early haematopoietic development.
Comprehensive bioinformatic analysis combined with experimental
assays not only provided new insights into the control of early
haematopoietic development by Runx1, but may also serve as a
blueprint for future analysis of additional key regulators.Gradual Runx1 recruitment to target genes during early development
By generating genome-scale data across four developmentally
related cell populations that represent the dynamics of early
Runx1 induction, we were able to monitor how Runx1 is recruited
to its ﬁrst physiological target genes. This analysis demonstrated
that robust Runx1 binding to most targets was only seen in the
fourth and most mature population. While the underlying
mechanisms remain to be elucidated, one of the most likely
explanations may be that, following the ﬁrst production of Runx1
protein during development, initial Runx1–DNA interactions may
be short-lived and therefore not readily identiﬁed by ChIP. Indeed,
this notion is supported by the observation that most regions
called as peaks only in population 4 already have some
Fig. 8. (A) Time course analysis of CD41 expression in early mouse embryos. (A) CD41 and VE-cadherin expression were analysed by ﬂow cytometry between E7.0 and
E8.25 of mouse embryonic development. Seven distinct developmental stages between E7.0 and E8.5 were analysed. A distinct CD41 bright population only becomes
clearly separable by FACS at the ES stage. LS¼ late streak stage, NP¼neural plate stage, EHF¼early head fold stage, LHF¼ late head fold stage, ES¼early somite pair stage
(0–1 somite pairs), 4sp¼approximately 3–4 somite pair stage, 7sp¼7 somite pair stage. The Runx1þ / and Runx1/ embryos analysed in Fig. 6 are approximately
equivalent to the NP stage. Each FACS plot of LS–LHF stage embryos is from 8–10 pooled stage-matched whole embryos. Each FACS plot from somite pair stage embryos is
from 4–6 pooled stage-matched yolk sacs. All embryos are from females crossed with GFP-transgenic males to avoid contamination of maternal cells. (B) FACS analysis of
E7.5 and E8.5 Runx1-Venus knock-in heterozygous and homozygous mouse embryos. Embryos were dissected and carefully staged. Dissociated cells were analysed by
FACS using antibodies against CD41 in combination with anti-CD31 and cKit as well as Runx1-Venus ﬂuorescence. Homozygous Runx1 knock-out embryos show a severe
reduction in CD41 positive cells, and a complete absence of cKit-high/CD41þ cells. (C) Q-RT-PCR analysis of Runx1 reactivation. Sorted day 4 Flk1þ cells from OP9 co-
culture of Runx1-reactivable ES cells (Runx1SACRE/LacZ ES cells) were replated on collagen type IV dishes with or without 4OH-tamoxifen. Cells were harvested for RNA
isolation after 24 h and 48 h (see Supplementary Fig. 9 for detailed experimental outline).
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the earliest Runx1 expressing population 2 (see Fig. 2A). Short-
lived ‘priming’ interactions involving Runx1 have been reported
previously in a detailed analysis of Runx1 recruitment to the
Pu.1–14 URE enhancer (Hoogenkamp et al., 2009). The genome-
scale analysis reported here suggests that gradual recruitment of
Runx1 is a widespread phenomenon. Importantly however, 100
Runx1 target regions showed robust binding already in the earlier
populations suggesting a diversity of mechanisms for Runx1
recruitment, possibly depending on whether or not a given target
region has already been ‘opened up’ by prior binding of other
factors. It is likely that future studies with increased sequencing
depth will identify additional low-level/short-lived binding
events for Runx1 as well as other key transcriptional regulators.
Identiﬁcation of physiological Runx1 targets through genome-scale
timecourse analysis of early haematopoietic development
Experimental strategies for the identiﬁcation of transcription
factor target genes commonly involve perturbation analysis,
where expression changes of candidate target genes are taken
as evidence for a regulatory connection with the upstream
transcription factor. However, perturbation of Runx1 during early
haematopoietic development fundamentally changes the cellular
phenotypes of early progenitor cell populations, and therefore
represents a potential impediment towards the identiﬁcation of
physiological target genes. We therefore elected to generate
genome-wide expression and ChIP-Seq time-course data from
normal cells as well as expression data from ﬂow-sorted Runx1þ /
and Runx1/ cell populations from E7.5 early embryos in order to
identify a high-conﬁdence Runx1 target gene set.
The validity of the above approach is illustrated by the following
points: (i) our high-conﬁdence target gene list included Pu.1/Sfpi1
and Runx1 itself, and therefore contained the two early Runx1
targets known previously. (ii) CD41 had previously been categorised
as a direct Scl target gene in ES-cell differentiation assays, yet its
dependence on Runx1 activity appeared to differ depending on the
type of ES-cell differentiation assay used (Mikkola et al., 2003;
Lancrin et al., 2009). The genome-scale data presented here sug-
gested that Runx1 is indeed important for early CD41 expression,
which we validated in vivo by showing that E7.5Runx1/ embryos
do not express signiﬁcant levels of CD41 even though they are
known to express Scl. (iii) A recent study overexpressing Runx1 in
haemangioblasts suggested that Runx1 may repress endothelial
genes (Sakai et al., 2009). Interestingly, there was a highly signiﬁcant
overlap (P-value 1.7e12) between this study and the Runx1
negatively correlated genes reported here, which included Sox17,
ectopic expression of which was recently shown to induce apoptosis
in early ES cell-derived blood progenitors (Serrano et al., 2010).
Direct repression of Sox17 by Runx1 is therefore consistent with the
known function of Runx1 as a positive driver of early haematopoie-
tic speciﬁcation, and underscores the notion that this important
function of Runx1 may include repression as well as activation of
target genes.
Sequential deployment of regulatory circuits during a developmental
time course
Recent large scale regulatory network studies in lower model
organisms have revealed that tissue-speciﬁc gene expression is
controlled by densely connected networks of TFs which directly
control downstream effector genes rather than operating through
extended regulatory cascades (Davidson, 2010; Roy et al., 2010;
Wilson et al., 2011). However, it is currently not known how these
densely connected multi TF networks are established during the
speciﬁcation of cell types from undifferentiated pluripotentprogenitors, which typically do not express any of these major
tissue-speciﬁc TFs. Of note, expression of the various lineage-
speciﬁc transcription factors is typically initiated at different
time-points during tissue speciﬁcation. For example, whereas all
members of the previously described Scl/Gata2/Fli1 haemangio-
blast triad are expressed prior to Runx1, we have shown here that
other regulators such as Pu.1 and Gﬁ1b follow the Runx1 pattern.
Given that the latter two were also direct Runx1 targets, our
results are consistent with a model whereby individual subcir-
cuits are activated sequentially during increasing differentiation
towards haematopoietic fate. The mechanisms underlying step-
wise activation of the proposed core circuits represent important
targets for future investigation, with the recent demonstration of
Runx1 repression by HoxA3 in haemangioblasts providing a
potentially very signiﬁcant ﬁrst clue (Iacovino et al., 2011).
Comparison of genome-scale data during haematopoietic spe-
ciﬁcation (this paper) with data from fully speciﬁed blood
progenitor cells (Wilson et al., 2010a) demonstrated that many
of the early Runx1 targets are targets of both Runx1 and the
Scl/Gata2/Fli1 triad in fully speciﬁed haematopoietic progenitor
cells (see Fig. 4). These genes correlate with Runx1 expression
during early haematopoietic speciﬁcation, thus suggesting that
even though they ultimately end up downstream of the Scl/Gata2/
Fli1 triad, this triad is not sufﬁcient to initiate their expression,
which by contrast appears to require Runx1. This hypothesis was
indeed corroborated through our complementary in vitro and
in vivo analysis of CD41 regulation. A model is therefore emerging
whereby key regulators or small regulatory core circuits are
activated sequentially during development, yet end up controlling
target genes collectively. Within a fully speciﬁed tissue therefore,
developmental regulatory cascades effectively collapse into one
large and densely connected TF network, which directly controls
expression of tissue speciﬁc effector genes.
One important mechanism involved in stabilising these large
transcription factor networks is likely to be extensive protein-
protein interactions, new examples of which continue to be dis-
covered (Wilson et al., 2010a; Palii et al., 2011) including the recent
demonstration of Runx1–Gata2 interactions which would link
Runx1 with the earlier haemangioblast core circuit. The resultant
crosstalk would have the capacity to stabilise emerging regulatory
networks assembled from sequentially activated individual TFs or
small core circuits. Validation of this model will require time-course
analysis of multiple key regulatory TFs in addition to the data on
Runx1 presented here. Nevertheless, the comprehensive genome-
scale analysis of Runx1-centric gene expression and ChIP-Seq data
reported here illustrates the power of this approach; not only to
enhance our understanding of the functionality of an individual
regulator, but also to gain potentially widely applicable insights into
the transcriptional control of mammalian development.Authorship contributions
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